China Resources Pharmaceutical Group Ltd
HKEX:3320
| US |
|
Fubotv Inc
NYSE:FUBO
|
Media
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
| US |
|
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
| CN |
|
NIO Inc
NYSE:NIO
|
Automobiles
|
| US |
|
Fluor Corp
NYSE:FLR
|
Construction
|
| US |
|
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
| US |
|
TopBuild Corp
NYSE:BLD
|
Consumer products
|
| US |
|
Abbott Laboratories
NYSE:ABT
|
Health Care
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
| US |
|
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
| US |
|
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
| US |
|
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
| US |
|
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
| US |
|
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
4.51
6.99
|
| Price Target |
|
We'll email you a reminder when the closing price reaches HKD.
Choose the stock you wish to monitor with a price alert.
|
|
Fubotv Inc
NYSE:FUBO
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
C
|
C3.ai Inc
NYSE:AI
|
US |
|
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
|
NIO Inc
NYSE:NIO
|
CN |
|
|
Fluor Corp
NYSE:FLR
|
US |
|
|
Jacobs Engineering Group Inc
NYSE:J
|
US |
|
|
TopBuild Corp
NYSE:BLD
|
US |
|
|
Abbott Laboratories
NYSE:ABT
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
|
|
Occidental Petroleum Corp
NYSE:OXY
|
US |
|
|
Matrix Service Co
NASDAQ:MTRX
|
US |
|
|
Automatic Data Processing Inc
NASDAQ:ADP
|
US |
|
|
Qualcomm Inc
NASDAQ:QCOM
|
US |
|
|
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
China Resources Pharmaceutical Group Ltd
Operating Income
China Resources Pharmaceutical Group Ltd
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
C
|
China Resources Pharmaceutical Group Ltd
HKEX:3320
|
Operating Income
HK$19.6B
|
CAGR 3-Years
23%
|
CAGR 5-Years
10%
|
CAGR 10-Years
N/A
|
|
|
G
|
Grand Pharmaceutical Group Ltd
HKEX:512
|
Operating Income
HK$2.7B
|
CAGR 3-Years
9%
|
CAGR 5-Years
17%
|
CAGR 10-Years
26%
|
|
|
S
|
SSY Group Ltd
HKEX:2005
|
Operating Income
HK$1.7B
|
CAGR 3-Years
28%
|
CAGR 5-Years
6%
|
CAGR 10-Years
13%
|
|
|
U
|
United Laboratories International Holdings Ltd
HKEX:3933
|
Operating Income
¥3.7B
|
CAGR 3-Years
39%
|
CAGR 5-Years
33%
|
CAGR 10-Years
13%
|
|
|
Sino Biopharmaceutical Ltd
HKEX:1177
|
Operating Income
¥6.2B
|
CAGR 3-Years
7%
|
CAGR 5-Years
5%
|
CAGR 10-Years
14%
|
|
|
H
|
HUTCHMED (China) Ltd
HKEX:13
|
Operating Income
-$120.8m
|
CAGR 3-Years
23%
|
CAGR 5-Years
-2%
|
CAGR 10-Years
-77%
|
|
China Resources Pharmaceutical Group Ltd
Glance View
China Resources Pharmaceutical Group Ltd. is an investment holding, which engages in the research and development, manufacture, distribution, and retail of pharmaceutical and healthcare products. The Company, along with its subsidiaries, is principally engaged in the research and development, manufacturing, distribution and retail of pharmaceutical and other healthcare products. The firm mainly operates through three segments. Pharmaceutical Manufacturing segment is engaged in the research and development, manufacturing and sale of pharmaceutical and other healthcare products. Pharmaceutical Distribution segment is engaged in the provision of distribution solutions to pharmaceutical manufacturers and dispensers, such as hospitals and other medical institutions, distributors and retail pharmacies. Pharmaceutical Retail segment is involved in the operation of retail pharmacies in China and Hongkong.
See Also
What is China Resources Pharmaceutical Group Ltd's Operating Income?
Operating Income
19.6B
HKD
Based on the financial report for Jun 30, 2024, China Resources Pharmaceutical Group Ltd's Operating Income amounts to 19.6B HKD.
What is China Resources Pharmaceutical Group Ltd's Operating Income growth rate?
Operating Income CAGR 5Y
10%
Over the last year, the Operating Income growth was 15%. The average annual Operating Income growth rates for China Resources Pharmaceutical Group Ltd have been 23% over the past three years , 10% over the past five years .
You don't have any saved screeners yet
